Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 2, 2001
Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strainsF Paradisi, G Corti, R Cinelli
The Medical Clinics of North America|February 24, 2001
Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibioticsF Paradisi, G Corti, D Messeri
International Journal of Antimicrobial Agents|December 19, 2000
Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibioticG Corti, R Cinelli, F Paradisi
La Ricerca in Clinica E in Laboratorio|July 1, 1983
The influence of in vivo pretreatment of cyclophosphamide on phagocytic activity of mouse macrophages in vitroN Forte, L Lombardi, F Paradisi
Applied Microbiology and Biotechnology|March 17, 2019
Haloferax volcanii as immobilised whole cell biocatalyst: new applications for halophilic systemsR U Haque, F Paradisi, T Allers
Pathologie-Biologie|February 1, 1975
A cytochemical study of some enzyme activities in biliverdin-treated cell culturesF Paradisi, L Graziano, F de Ritis
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|April 1, 1985
Aztreonam in the therapy of nosocomial infections in patients with impaired host defensesP Cristiano, M R Iovene, F Paradisi
Applied Microbiology and Biotechnology|December 22, 2019
Haloferax volcanii for biotechnology applications: challenges, current state and perspectivesR U Haque, F Paradisi, T Allers
Minerva Medica|January 1, 1989
[Multicenter research on cefoperazone efficacy and tolerance in the therapy of urinary and respiratory infections]F Paradisi, G de Crescenzo, M P Ruffilli
La Ricerca in Clinica E in Laboratorio|April 1, 1976
Ultrastructural changes in HEp-2 cells treated with staphylococcal alpha-toxinF Paradisi, P Barsotti, A Cifarelli, et al.
Pageof 9